Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MK2 inhibitor ATI-2231

An orally bioavailable inhibitor of mitogen-activated protein (MAP) kinase-activated protein kinase 2 (MAPKAPK2; MK2), with potential antineoplastic and chemosensitization activities. Upon oral administration, MK2 inhibitor ATI-2231 targets and binds to the p38MAPK-MK2 complex, thereby inhibiting the p38MAPK phosphorylation and activation of MK2. This inhibits p38MAPK/MK2-mediated signaling pathway, and abrogates the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis, and may potentiate the cytotoxicity of DNA-damaging agents. MK2, a cell cycle checkpoint kinase, plays an important role in DNA repair.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:ATI 2231
ATI-2231
ATI2231
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search